Galderma has secured manufacturing license updates from the Swedish Medical Products Agency, enabling the company to advance its ambitious growth and innovation agenda.
These updates followed a rigorous good manufacturing practices (GMP) inspection of Galderma’s Uppsala, Sweden, centre of excellence, the company said in a news release.
The updated licenses authorize Galderma to manufacture and conduct bioanalytical testing on RelabotulinumtoxinA (QM1114), a next-generation liquid neuromodulator developed with Galderma’s proprietary PEARL technology.
This innovative technology maintains the molecule’s integrity, resulting in a highly active, complex-free botulinum toxin A, marking a significant advancement in Injectable Aesthetics.
Adrian Murphy, head of Global Operations at Galderma, emphasised the significance of these updates: “Our commitment to leading innovation in dermatology is reflected in our high-performance operations.”
He continued, “These new license updates granted by the Swedish authorities reflect Galderma’s skills and the capacities we are building to support our rapid growth trajectory.”
“As we work to extend our category leadership globally, these new capabilities will increase Galderma’s autonomy to manufacture and commercialize the next generation of scientifically differentiated innovations in dermatology.”
The Uppsala Centre of Excellence is one of four state-of-the-art manufacturing and R&D facilities operated by Galderma worldwide.
Currently undergoing an expansion to meet the rising global demand for science-based premium dermatology solutions, the new facility is set for completion by the end of 2025.
It is strategically designed to support the higher demand for injectable aesthetics treatments and future product developments.
The modular design of the facility allows for seamless future expansions, aligning with Galderma’s growth strategy and its environmental, social, and governance (ESG) roadmap.
RelabotulinumtoxinA, developed by Galderma, is a highly active, innovative, complex-free, and ready-to-use liquid botulinum toxin A with a proprietary strain. Its unique liquid formulation eliminates the need for reconstitution from powder, reducing variability, errors, and risks associated with reconstitution. This ensures improved consistency of results.
Currently under global investigation, RelabotulinumtoxinA aims to expand Galderma’s neuromodulator portfolio, contributing to the broadest injectable aesthetics portfolio on the market.
